ATE226823T1 - Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten - Google Patents

Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten

Info

Publication number
ATE226823T1
ATE226823T1 AT99909110T AT99909110T ATE226823T1 AT E226823 T1 ATE226823 T1 AT E226823T1 AT 99909110 T AT99909110 T AT 99909110T AT 99909110 T AT99909110 T AT 99909110T AT E226823 T1 ATE226823 T1 AT E226823T1
Authority
AT
Austria
Prior art keywords
combination
alpha
nicotinergic
gaba
agonists
Prior art date
Application number
AT99909110T
Other languages
English (en)
Inventor
Gerard Raphael Dawson
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE226823T1 publication Critical patent/ATE226823T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99909110T 1998-03-16 1999-03-16 Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten ATE226823T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9805559.3A GB9805559D0 (en) 1998-03-16 1998-03-16 A combination of therapeutic agents
PCT/GB1999/000800 WO1999047142A1 (en) 1998-03-16 1999-03-16 Combination of a gaba-a alpha 5 inverse agonist and a nicotinic agonist

Publications (1)

Publication Number Publication Date
ATE226823T1 true ATE226823T1 (de) 2002-11-15

Family

ID=10828630

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99909110T ATE226823T1 (de) 1998-03-16 1999-03-16 Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten

Country Status (9)

Country Link
EP (1) EP1061925B1 (de)
JP (1) JP2002506822A (de)
AT (1) ATE226823T1 (de)
AU (1) AU752013B2 (de)
CA (1) CA2324237A1 (de)
DE (1) DE69903716T2 (de)
ES (1) ES2185321T3 (de)
GB (1) GB9805559D0 (de)
WO (1) WO1999047142A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
AU2001264932A1 (en) 2000-05-26 2001-12-11 Neurogen Corporation Oxo-imidazopyrimidine-carboxamides and their use as gaba brain receptor ligands
AU2001273639A1 (en) 2000-06-26 2002-01-08 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
GB9503601D0 (en) * 1995-02-23 1995-04-12 Merck Sharp & Dohme Method of treatment and method of manufacture of medicament
WO1998004560A1 (en) * 1996-07-25 1998-02-05 Merck Sharp & Dohme Limited SUBSTITUTED TRIAZOLO PYRIDAZINE DERIVATIVES AS INVERSE AGONISTS OF THE GABAAα5 RECEPTOR SUBTYPE

Also Published As

Publication number Publication date
GB9805559D0 (en) 1998-05-13
AU2847799A (en) 1999-10-11
EP1061925B1 (de) 2002-10-30
WO1999047142A1 (en) 1999-09-23
JP2002506822A (ja) 2002-03-05
AU752013B2 (en) 2002-09-05
ES2185321T3 (es) 2003-04-16
CA2324237A1 (en) 1999-09-23
DE69903716D1 (de) 2002-12-05
DE69903716T2 (de) 2003-08-14
EP1061925A1 (de) 2000-12-27

Similar Documents

Publication Publication Date Title
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
DZ2618A1 (fr) Emploi des antagonistes des récepteurs de 5-HT3 dans le traitement de la colopathie.
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
DE69528823D1 (en) Morpholinwirkstoffvorläufer als tachykininreceptorantagonisten
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
TR199801348T2 (xx) Heterosikl-kondanse morfinoid t�revleri(II).
DK0804196T3 (da) Anvendelse af serotoninantagonister (5HT 3) til behandling af fibromyalgia
DE69934241D1 (de) Agonistische antikörper gegen tie2
ATE359076T1 (de) Mittel gegen juckreiz
ATE247470T1 (de) Neue substituierte imidazolverbindungen
PT935465E (pt) Compostos novos de imidazole substituido
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
PT772603E (pt) Compostos substituidos de pirimidina e sua utilizacao
PT951282E (pt) Prevenção e tratamento de doenças esqueléticas com agonistas e2 de protaglandinas selectivos do subtipo de receptores ep2
DE59605568D1 (de) Benzonitrile als 5-HT Agonisten und Antagonisten
EA199900362A1 (ru) Новые соединения, полезные для использования в качестве нейрозащитных средств
BG105256A (en) Muscarinic agonists and antagonists
BR9510499B1 (pt) antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados por il-5.
DK0615751T3 (da) Anvendelse af tachykininantagonister til behandling af emesis
BR9402890A (pt) Composição de lubrificante baseado em siloxano no segregador de hidrogênio.
ATE226823T1 (de) Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten
BR9612283A (pt) Composição para o tratamento de manchas em peças de roupa e métodos de tratamento

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties